Ms. Xue Ping, the chairman of the board, and the executives of Meditech warmly welcomed the Global Fund procurement team on 2nd August.
The Global Fund (The Global Fund to Fight AIDS, Tuberculosis and Malaria) is an international financing organization that aims to attract, leverage and invest additional resources to end the epidemics of HIV/AIDS, tuberculosis and malaria to support attainment of the Sustainable Development Goals. Since establishment in 2002, the Global Fund has been fighting the world's worst diseases with supports and donations from institutions and individuals. And now it covers more than 150 countries and regions. The team visited Hall of Corporate Culture, workshops, etc. and had comprehensive communications with Meditech.
Both parties agreed to give full play to resource and platform advantages, and focus on strengthening mutually beneficial cooperation and win-win in medical oxygen generation system projects. Meditech has established a good image of Chinese brand and fully reflects the conscious responsibility of China as a responsible power.
The Global Fund team spoke highly of Meditech’s product layout, R&D capabilities, industry influence and future development prospects. The team also pointed out that the oxygen generation system products of Meditech are in line with the development positioning of the Global Fund, and is willing to establish a deeper and closer cooperative relationship with Meditech in the next step.
Being the only Chinese PSA manufacturer in the ACT program initiated by WHO, UN agencies, World Bank, The Global Fund and other international organizations is another big leap. It perfectly reflects Meditech’s 20 years of effort.
Post time: Nov-16-2022